Travere Therapeutics, Inc. (Nasdaq: TVTX) today presented new biomarker data from the Phase 3 PROTECT Study providing ...

Travere Therapeutics reported durable biomarker data for FILSPARI in IgA nephropathy, but shares fell 4.5% as markets focus ...

Travere Therapeutics presented Phase 3 PROTECT biomarker findings suggesting FILSPARI may modify underlying disease ...

CBOE Global (CBOE) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results ...

AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing ...

With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Get the detailed balance sheet for Travere Therapeutics, Inc. (TVTX). Up to 10 years of financial statements. Quarterly or ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The FDA has approved Ultomiris to reduce proteinuria in adult patients with primary immunoglobulin A, or IgA, nephropathy who ...

Genesis Healthcare, Inc. (Genesis) today announced that its chapter 11 plan became effective, following the closing of the sale of substantially all of its operating assets to 101 W.